How Much Does Saxenda Cost in South Dakota in 2026?

Saxenda Retail Pricing in South Dakota

The manufacturer list price set by Novo Nordisk for Saxenda is $1,349 per month, covering one five-pen carton of liraglutide 3 mg injection pens. South Dakota retail pharmacies, including chains like Lewis Drug, Hy-Vee Pharmacy, and Walgreens locations in Sioux Falls and Rapid City, generally charge at or near this list price for cash-pay customers.

This price has remained consistent through early 2026. Saxenda's pricing sits below newer GLP-1 receptor agonists approved for obesity: semaglutide 2.4 mg (Wegovy) lists at approximately $1,349 per month as well, while tirzepatide (Zepbound) lists at $1,059.87 per month according to Eli Lilly's published pricing. Liraglutide was initially approved for type 2 diabetes at lower doses (Victoza, 1.8 mg) before the FDA approved the 3 mg formulation specifically for chronic weight management in December 2014 based on the SCALE clinical trial program.

Price differences across South Dakota pharmacies are minimal for brand-name Saxenda, but GoodRx and similar discount platforms occasionally list coupons bringing the cash price to $1,100 to $1,250 at select locations. These coupons cannot be stacked with insurance or the manufacturer savings card.

Insurance Coverage for Saxenda in South Dakota

Commercial insurance plans in South Dakota vary widely in their coverage of anti-obesity medications. Large employer-sponsored plans through carriers like Avera Health Plans, Sanford Health Plan, and Blue Cross Blue Shield of South Dakota may include Saxenda on formulary, but almost all require prior authorization and documentation of failed lifestyle interventions.

Typical insurer requirements include a confirmed BMI of 30 or greater (or 27 with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia), a documented 3- to 6-month trial of diet and exercise, and ongoing follow-up visits demonstrating continued weight loss. The Endocrine Society's 2015 clinical practice guideline on pharmacological management of obesity recommends anti-obesity medications as adjuncts to lifestyle modification for patients with BMI ≥30 or ≥27 with comorbidities, supporting these coverage criteria [3]. The American Association of Clinical Endocrinology (AACE) and American College of Endocrinology issued a 2016 comprehensive clinical practice guideline reinforcing this threshold.

Even when covered, copays and coinsurance often range from $75 to $300 per month. Patients should request a formulary exception or tier reduction if Saxenda is placed on a non-preferred specialty tier. A 2021 coverage analysis published in Obesity found that only 11% of marketplace plans explicitly covered any anti-obesity medication without prior authorization [4].

South Dakota Medicaid and Saxenda

South Dakota Medicaid does not cover Saxenda for chronic weight management. This is consistent with most state Medicaid programs; a 2019 analysis of Medicaid formularies found that fewer than half of state Medicaid programs covered FDA-approved anti-obesity medications.

South Dakota expanded Medicaid eligibility in 2023 under voter-approved Amendment D, increasing the number of enrolled adults. The expanded program still excludes weight-management drugs from its formulary. The federal Medicaid statute has historically treated anti-obesity medications as optional, and the Centers for Medicare & Medicaid Services has not mandated coverage. Medicare Part D similarly excludes drugs used for "anorexia, weight loss, or weight gain" under Section 1862(a)(1)(A) of the Social Security Act, though bipartisan legislation (the Treat and Reduce Obesity Act) has been reintroduced in Congress multiple sessions running.

Patients enrolled in South Dakota Medicaid who need pharmacotherapy for obesity may explore whether their prescriber can document a secondary indication. Liraglutide at lower doses (Victoza, 1.8 mg) is FDA-approved for type 2 diabetes and may be covered under Medicaid when prescribed for glycemic control rather than weight management.

The Novo Nordisk Savings Card

Novo Nordisk offers a manufacturer savings card that can reduce Saxenda's out-of-pocket cost to as low as $25 per fill for commercially insured patients. The card covers up to $200 off each 30-day prescription, renewable monthly for up to 12 consecutive months.

Eligibility requirements: the patient must have commercial (private) insurance, must not be enrolled in any federal or state healthcare program (Medicare, Medicaid, TRICARE, VA), and must have a valid prescription for Saxenda. The card is accepted at all major South Dakota pharmacies. Patients can obtain the card through the Novo Nordisk patient assistance website or through their prescribing clinician.

For uninsured patients, Novo Nordisk's Patient Assistance Program (PAP) provides Saxenda at no cost to qualifying individuals with household incomes at or below 400% of the federal poverty level. This requires an application with income verification and prescriber attestation. Processing typically takes 4 to 6 weeks.

SCALE Trial: The Clinical Evidence Behind Saxenda

The FDA's 2014 approval of Saxenda rested primarily on the SCALE (Satiety and Clinical Adiposity, Liraglutide Evidence) trial program. The key SCALE Obesity and Prediabetes trial, published in the New England Journal of Medicine in 2015, randomized 3,731 adults without diabetes to liraglutide 3 mg or placebo, both combined with lifestyle counseling.

Results at 56 weeks: liraglutide 3 mg produced a mean weight loss of 8.0% of body weight versus 2.6% with placebo (P<0.001). A total of 63.2% of liraglutide-treated patients lost at least 5% of body weight, compared with 27.1% on placebo. The study also showed a 79% reduction in the rate of progression from prediabetes to type 2 diabetes over 3 years of follow-up [1].

A separate SCALE trial in patients with type 2 diabetes showed more modest weight loss (6.0% vs. 2.0% with placebo at 56 weeks), reflecting the known difficulty of weight reduction in the setting of insulin resistance and concomitant diabetes medications.

The FDA prescribing label for Saxenda notes the most common adverse effects as nausea (39.3%), diarrhea (20.9%), constipation (19.4%), vomiting (15.7%), and injection-site reactions (13.9%). The label carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies, though no causal link has been established in humans. A 2023 cohort study using Scandinavian cancer registry data found no increased risk of medullary thyroid carcinoma with GLP-1 receptor agonist use.

Compounded Liraglutide 3 mg in South Dakota

503A compounding pharmacies in South Dakota can legally prepare liraglutide 3 mg injections when a valid patient-specific prescription exists. Compounded versions are not FDA-approved and do not undergo the same regulatory review as brand-name Saxenda, but they offer a significantly lower price point for patients who cannot afford the brand product.

Compounded liraglutide pricing through 503A pharmacies ranges from approximately $150 to $450 per month depending on the compounding pharmacy, the specific formulation, and shipping costs. This represents savings of 67% to 89% compared with brand Saxenda's $1,349 list price.

The FDA's guidance on compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act requires that compounded drugs be prepared by a licensed pharmacist based on an individual prescription, use ingredients that meet USP standards, and not be copies of commercially available products unless the prescriber documents a clinical difference (such as an allergy to an inactive ingredient in the commercial product). South Dakota's Board of Pharmacy regulates 503A pharmacies within the state.

Patients considering compounded liraglutide should verify that the pharmacy holds current state licensure, uses USP-grade active pharmaceutical ingredients, and performs appropriate potency and sterility testing. The United States Pharmacopeia Chapter 797 sets sterility standards for compounded sterile preparations.

Telehealth Access to Saxenda in South Dakota

South Dakota permits telehealth prescribing of Saxenda. Clinicians licensed in South Dakota can evaluate patients via synchronous audio-video visits and issue prescriptions for liraglutide 3 mg without an in-person visit, consistent with South Dakota's telehealth parity law (SDCL 36-4-41.1) enacted in 2019.

Telehealth platforms operating in South Dakota must use prescribers licensed by the South Dakota Board of Medical and Osteopathic Examiners. HealthRX and other telehealth weight-management services can evaluate patients, review lab work, and prescribe Saxenda with delivery to any South Dakota address.

The American Telemedicine Association reports that telehealth utilization for chronic disease management has stabilized at approximately 15% of outpatient visits nationally since the post-pandemic normalization period. For anti-obesity medication management, telehealth visits are particularly practical because follow-up primarily involves weight tracking, side-effect assessment, and dose titration rather than physical examination.

How Saxenda Compares to Other Weight-Loss Medications Available in South Dakota

Saxenda is one of six FDA-approved anti-obesity medications currently available, each with distinct efficacy profiles and cost considerations.

Semaglutide 2.4 mg (Wegovy), also a GLP-1 receptor agonist, demonstrated superior weight loss in the STEP 1 trial (N=1,961): 14.9% mean body weight reduction at 68 weeks versus 2.4% with placebo. Wegovy is dosed weekly rather than daily, which some patients prefer. Its list price is comparable to Saxenda.

Tirzepatide (Zepbound), a dual GIP/GLP-1 receptor agonist, produced 20.9% weight loss at the highest dose (15 mg) in the SURMOUNT-1 trial (N=2,539) at 72 weeks. Zepbound is also a weekly injection and lists at $1,059.87 per month.

Oral semaglutide 50 mg (expected under review) and phentermine-topiramate ER (Qsymia) represent alternatives at different price points. Qsymia, available since 2012, is often the least expensive branded option at $150 to $250 per month but carries FDA-mandated REMS restrictions due to teratogenicity risk.

The 2022 American Gastroenterological Association guideline on pharmacological interventions for obesity recommends semaglutide 2.4 mg and tirzepatide as first-line pharmacotherapy options, with liraglutide 3 mg as a reasonable alternative for patients who prefer daily dosing or cannot access the newer agents.

Practical Steps to Reduce Saxenda Cost in South Dakota

Start by confirming your insurance formulary status. Call the number on the back of your insurance card and ask whether Saxenda (liraglutide 3 mg, NDC 0169-4060-12) is covered, what tier it occupies, and what prior authorization criteria apply.

If covered, apply for the Novo Nordisk savings card before filling your first prescription. Present the card at the pharmacy alongside your insurance card.

If not covered or uninsured, apply for the Novo Nordisk Patient Assistance Program. While your application processes, discuss compounded liraglutide 3 mg from a licensed 503A pharmacy with your prescriber as a bridge option.

Compare prices at South Dakota pharmacies using GoodRx, RxSaver, or SingleCare before each fill. Prices can shift monthly. Specialty pharmacies and mail-order options (such as OptumRx or Express Scripts) sometimes offer lower negotiated rates than retail locations.

If cost remains prohibitive, ask your clinician about switching to an alternative anti-obesity medication with a lower price point or better insurance coverage in your specific plan.